Sharon Huang is a venture investor at Tau Ventures who simultaneously continues her medical training at Mt. Sinai, giving her an unusual dual perspective as both a clinician-in-training and AI healthcare investor. She combines deep technical experience building automated sequencing pipelines at the Chan Zuckerberg Biohub with a systematic approach to healthcare investing that focuses on backend infrastructure and operational pain points rather than patient-facing applications.
About their Fund
Tau Ventures is an AI-first, seed-first fund ($85M+ AUM) co-founded by Amit Garg, whose background spans engineering at Nokia/Microsoft, health tech operations at Samsung Next, and hands-on angel investing, making it a practitioner-led fund that writes modest initial checks (~$500k) and focuses on AI companies transforming workflows in digital health, enterprise infrastructure, and automation rather than generic AI tooling. The fund operates with unusual transparency through public investment memos and podcast appearances that detail their exact investment logic, while maintaining an "AI-realistic" approach that emphasizes capital efficiency and measurable ROI over speculative narratives, particularly targeting companies that shift healthcare from reactive treatment to proactive, data-driven care delivery.




















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































